Key Links:

By Topic:

Search:

ICAAC 2005: Index of Coverage

Special Features

What Is the Most Important HIV Development of 2005? (December 19, 2005)
[Archived Article]
Researchers, physicians and other attendees of ICAAC 2005 are asked for their views; here's what they had to say.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy

Antiretrovirals in Development

BILR 355 BS, a Second-Generation NNRTI, Shows Activity Against Most Common NNRTI Mutations (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
New Protease Inhibitor Brecanavir Shown to Be Safe and Effective in Small Study (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy

Complications of HIV/HAART

More Questions Than Answers Regarding High Hepatic Event Rates Among Thai Patients in 2NN Study (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Benefit of Rosiglitazone or Metformin for Lipodystrophy Still Unclear (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Drugs to Reverse Lipoatrophy Show So-So Effects (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Ritonavir-Boosted Tipranavir Increases ALT and AST Levels in HIV/Hepatitis-Coinfected Patients (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Study Finds That Select NRTIs Do Not Harm Kidneys (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Tenofovir Proves Safe for Kidneys After Three Years of Use (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Spanish Study Finds Association Between Long-Term Treatment With Tenofovir and Kidney Toxicity Still Unclear (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Rub-a-Dub-Dub Away Those Annoying Sculptra Bumps! (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com

Drug Resistance

Analyzing the Pattern of Resistance Mutation Emergence of a Failing Abacavir + Lamivudine + Tenofovir Regimen Reveals a Possible Compensatory Mutation (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Researchers Uncover Possible Alternative Pathway to Tenofovir Resistance (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Small Study Suggests Genotypic Resistance Tests Maintain Accuracy Even When Viral Load Is Below 1,000 (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Rare Case of Protease Inhibitor Resistance After Failure of First-Line Boosted Fosamprenavir (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy

Treatment Strategies

Researchers Examine Use of Artificial Intelligence to Select Ideal Regimens for Treatment-Experienced Patients (December 17, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
[Archived Article]
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Severe Events Unrelated to AIDS or Antiretrovirals Were Most Common in Early HAART Patients (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Four-NRTI Regimen May Provide Simple Option for Treatment-Experienced Patients on Unduly Complex or Toxic Treatment (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Quadruple-NRTI Regimen No More Desirable Than Triple-NRTI Regimen in Treatment-Naive Patients, Study Finds (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Dual-Boosted Protease Inhibitor Regimen Shows Promise, but How Will It Be Used? (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Better Adherence With Once-Daily Versus Twice-Daily Lopinavir/Ritonavir: New Tablet Formulation Has Improved GI Tolerability (December 16, 2005)
[Archived Article]
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com
Two NRTIs or Three? Makes No Difference When Taken With Efavirenz, ACTG 5095 Finds (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
On TheBodyPRO.com

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.